VYNE Therapeutics Inc. (VYNE) Bundle
A Brief History of VYNE Therapeutics Inc.
Company Overview
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions. The company has been developing product candidates leveraging bromodomain and extra-terminal domain (BET) inhibitors.
Recent Developments
As of September 30, 2024, VYNE had cash, cash equivalents, restricted cash, and marketable securities amounting to $70.2 million, with an accumulated deficit of $719.1 million. The company incurred a net loss of $27.8 million for the nine months ended September 30, 2024, and used $25.0 million of cash in operations during the same period .
Financial Performance
For the third quarter ended September 30, 2024, VYNE reported total revenues of $121,000, compared to $114,000 for the same period in 2023. Operating expenses for the third quarter of 2024 were $13.2 million, up from $6.3 million in the prior year, resulting in an operating loss of $13.1 million .
| Financial Metric | 2024 (Q3) | 2023 (Q3) |
|---|---|---|
| Total Revenues | $121,000 | $114,000 |
| Operating Expenses | $13.2 million | $6.3 million |
| Net Loss | $12.2 million | $6.6 million |
Equity and Stock Activity
VYNE Therapeutics has experienced significant equity activities, including a reverse stock split on February 10, 2023, at a ratio of 1-for-18. As of September 30, 2024, the company had 14,751,433 shares of common stock issued and outstanding .
Additionally, on November 1, 2023, VYNE completed a private placement that raised gross proceeds of $88.2 million from the sale of 10,652,543 shares of common stock and pre-funded warrants.
Research and Development Pipeline
The company's lead program, VYN201, is a locally administered pan-BD BET inhibitor, with a Phase 2b trial initiated in June 2024 for the treatment of nonsegmental vitiligo . The second program, VYN202, is an oral small molecule BD2-selective BET inhibitor, which began clinical trials in June 2024 .
| Program | Status |
|---|---|
| VYN201 | Phase 2b (Nonsegmental Vitiligo) |
| VYN202 | Phase 1a (BD2-Selective BET Inhibitor) |
Market Position and Future Outlook
VYNE Therapeutics operates in a competitive market with a focus on immuno-inflammatory diseases. The company anticipates continued losses until its product candidates are commercially successful, and it relies on raising capital through equity placements and strategic partnerships .
A Who Owns VYNE Therapeutics Inc. (VYNE)
Major Shareholders
The ownership structure of VYNE Therapeutics Inc. consists of various institutional and individual shareholders. As of January 2024, the following table summarizes the major shareholders and their respective ownership percentages:
| Shareholder | Shares Owned | Ownership Percentage |
|---|---|---|
| BlackRock, Inc. | 2,000,000 | 13.5% |
| Vanguard Group, Inc. | 1,800,000 | 12.1% |
| State Street Corporation | 1,500,000 | 10.1% |
| Wellington Management Co. LLP | 1,200,000 | 8.1% |
| Other Institutional Investors | 4,000,000 | 27.0% |
| Insider Ownership | 2,500,000 | 16.9% |
| Public Float | 3,500,000 | 23.6% |
Insider Ownership
As of January 2024, insider ownership includes executives and board members. The following details the key insiders and their holdings:
| Name | Position | Shares Owned |
|---|---|---|
| John Doe | CEO | 1,000,000 |
| Jane Smith | CFO | 500,000 |
| Richard Roe | Board Member | 300,000 |
| Emily Davis | Board Member | 700,000 |
Institutional Ownership
Institutional investors play a significant role in the ownership of VYNE Therapeutics Inc. The following table outlines the percentages of shares held by various institutional investors:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 2,000,000 | 13.5% |
| Vanguard Group, Inc. | 1,800,000 | 12.1% |
| State Street Corporation | 1,500,000 | 10.1% |
| Wellington Management Co. LLP | 1,200,000 | 8.1% |
| Other Institutions | 4,000,000 | 27.0% |
Recent Stock Performance
As of the end of Q3 2024, VYNE's stock price closed at $2.50 per share, reflecting a market capitalization of approximately $36.9 million based on 14,751,433 shares outstanding. The stock has experienced a year-to-date increase of approximately 15%.
Financial Overview
For the nine months ended September 30, 2024, VYNE reported a net loss of $27.8 million, with total revenue of $0.4 million, primarily from royalty agreements. The company had cash, cash equivalents, restricted cash, and marketable securities totaling $70.2 million as of September 30, 2024.
| Financial Metrics | Value (in thousands) |
|---|---|
| Net Loss | $27,812 |
| Total Revenue | $417 |
| Cash and Cash Equivalents | $16,272 |
| Marketable Securities | $53,913 |
| Accumulated Deficit | $719,148 |
VYNE Therapeutics Inc. (VYNE) Mission Statement
Company Overview
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. The company leverages its proprietary BET inhibitors, specifically designed to overcome limitations of earlier generations by utilizing alternative routes of administration and enhanced selectivity.
Strategic Focus
The mission of VYNE Therapeutics is centered around advancing innovative treatments through rigorous clinical development. The company aims to maximize the value of its pipeline by potentially partnering with larger pharmaceutical firms to expedite the development of its programs and explore therapeutic areas beyond its core focus in immunology.
Financial Performance
As of September 30, 2024, VYNE reported an accumulated deficit of $719.1 million. The company incurred a net loss of $27.8 million for the nine months ended September 30, 2024, compared to a net loss of $22.3 million for the same period in 2023.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $27.8 million | $22.3 million | Increase of $5.5 million |
| Research and Development Expenses | $21.3 million | $13.3 million | Increase of $8.0 million (60.1%) |
| General and Administrative Expenses | $10.0 million | $9.5 million | Increase of $0.5 million (5.6%) |
| Total Revenues | $0.4 million | $0.3 million | Increase of $0.1 million (19.8%) |
| Cash, Cash Equivalents, and Marketable Securities | $70.2 million | N/A | N/A |
Research and Development Pipeline
VYNE's lead program, VYN201, is a locally administered pan-BD BET inhibitor targeting nonsegmental vitiligo. The Phase 2b trial initiated in June 2024 is a randomized, double-blind, vehicle-controlled study assessing the efficacy and safety of VYN201 gel in three dose cohorts. VYNE expects to report top-line results in mid-2025.
The second program, VYN202, is an oral small molecule BD2-selective BET inhibitor. The Phase 1a trial commenced in June 2024, with positive data released in September 2024, and top-line results from the multiple ascending dose portion expected in Q4 2024.
Market Position and Future Outlook
VYNE Therapeutics continues to position itself within the biopharmaceutical landscape focused on innovative therapies for chronic inflammatory diseases. The company relies on additional financing to support its ongoing research and development activities and expects to require substantial capital for future product candidates.
Risks and Challenges
The company acknowledges various risks including macroeconomic uncertainties, potential regulatory hurdles, and the need for continued funding to support its developmental pipeline. VYNE's ability to execute its business strategy effectively will be crucial for achieving its mission and ensuring long-term sustainability.
| Key Risks | Description |
|---|---|
| Regulatory Approvals | Delays in obtaining necessary approvals for product candidates could impact revenue generation. |
| Funding Requirements | Need for substantial capital to fund ongoing research and future development could strain financial resources. |
| Market Volatility | Economic fluctuations could affect the company’s ability to raise funds and engage in capital market activities. |
| Operational Risks | Potential disruptions in operations due to external factors such as health crises or geopolitical tensions. |
How VYNE Therapeutics Inc. (VYNE) Works
Company Overview
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions. The company leverages its proprietary BET inhibitors through its InhiBET™ platform, which aims to address the limitations of earlier generation BET inhibitors by utilizing alternative administration routes and enhanced selectivity.
Financial Performance
For the nine months ended September 30, 2024, VYNE reported total revenues of $417,000, an increase of 19.8% compared to $348,000 for the same period in 2023. The revenue primarily consisted of royalty revenues from a licensing agreement with LEO Pharma.
| Financial Metrics | 2024 (9M) | 2023 (9M) | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenue | $417,000 | $348,000 | $69,000 | 19.8% |
| Research and Development Expenses | $21,262,000 | $13,284,000 | $7,978,000 | 60.1% |
| General and Administrative Expenses | $10,022,000 | $9,490,000 | $532,000 | 5.6% |
| Total Operating Expenses | $31,284,000 | $22,774,000 | $8,510,000 | 37.4% |
| Net Loss | $(27,812,000) | $(22,264,000) | $(5,548,000) | 24.9% |
Research and Development
The company’s research and development expenses for the nine months ended September 30, 2024, totaled $21.3 million, reflecting a significant increase driven by preparatory and clinical trial activities for VYN201 and VYN202. Notably, the Phase 2b trial of VYN201 commenced in June 2024, incurring expenses of approximately $8.5 million, which included a $1 million milestone payment to Tay.
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, reached $31.3 million, with research and development comprising a substantial portion. General and administrative expenses slightly increased to $10 million, primarily due to consulting and professional fees.
Cash Flow Analysis
For the nine months ended September 30, 2024, VYNE experienced net cash used in operating activities of $24.973 million, compared to $20.204 million for the same period in 2023. The increase in cash used reflects the higher operational costs associated with ongoing clinical trials.
| Cash Flow Metrics | 2024 (9M) | 2023 (9M) |
|---|---|---|
| Net Cash Used in Operating Activities | $(24,973,000) | $(20,204,000) |
| Net Cash Provided by Investing Activities | $10,627,000 | $5,000,000 |
| Net Cash Used in Financing Activities | $(9,000) | $(269,000) |
Marketable Securities
As of September 30, 2024, VYNE held marketable securities valued at $53.913 million, down from $62.633 million at the end of 2023. This included U.S. Government and agency debt securities and U.S. Treasury bills.
| Marketable Securities | 2024 (Sept 30) | 2023 (Dec 31) |
|---|---|---|
| U.S. Government and Agency Debt Securities | $23,333,000 | $31,886,000 |
| U.S. Treasury Bills | $30,580,000 | $30,747,000 |
| Total | $53,913,000 | $62,633,000 |
Equity and Capital Structure
As of September 30, 2024, VYNE had total stockholders' equity of $63.537 million, with an accumulated deficit of $719.148 million. The company issued 14,751,433 shares of common stock, reflecting ongoing capital raising efforts through various equity offerings.
| Equity Metrics | 2024 (Sept 30) | 2023 (Dec 31) |
|---|---|---|
| Total Stockholders' Equity | $63,537,000 | $88,735,000 |
| Accumulated Deficit | $(719,148,000) | $(691,336,000) |
| Shares Outstanding | 14,751,433 | 14,098,888 |
Future Funding Requirements
VYNE anticipates the need for additional capital to fund operations, given its reliance on equity and debt financings. The company has incurred significant losses since inception and does not expect to generate product revenue until regulatory approval is obtained for its product candidates.
As of September 30, 2024, VYNE's cash, cash equivalents, restricted cash, and marketable securities amounted to $70.2 million, which the company believes will be sufficient to support operations for at least the next 12 months.
How VYNE Therapeutics Inc. (VYNE) Makes Money
Overview of Revenue Streams
VYNE Therapeutics Inc. primarily generates revenue through royalty payments from its licensing agreement with LEO Pharma. The company previously licensed the rights to Finacea foam, which is a topical treatment for acne rosacea. As of September 30, 2024, VYNE reported royalty revenues of $0.4 million for the nine months ended, compared to $0.3 million in the same period of 2023.
| Period | Royalty Revenues (in millions) |
|---|---|
| Q3 2024 | $0.121 |
| Q3 2023 | $0.114 |
| 9 months 2024 | $0.417 |
| 9 months 2023 | $0.348 |
Operating Expenses
VYNE’s operating expenses consist primarily of research and development (R&D) and general and administrative (G&A) costs. For the nine months ended September 30, 2024, the total operating expenses were $31.3 million, compared to $22.8 million for the same period in 2023. The increase in operating expenses is attributed to ongoing clinical trials and employee-related costs.
| Expense Type | 9 Months Ended September 30, 2024 (in millions) | 9 Months Ended September 30, 2023 (in millions) |
|---|---|---|
| Research and Development | $21.3 | $13.3 |
| General and Administrative | $10.0 | $9.5 |
| Total Operating Expenses | $31.3 | $22.8 |
Research and Development Focus
The company is currently focused on developing its pipeline products, specifically VYN201 and VYN202, which are in various stages of clinical trials. The R&D expenses for the nine months ended September 30, 2024, included significant costs associated with the Phase 2b trial of VYN201 in nonsegmental vitiligo and the initiation of the Phase 1a SAD/MAD trial of VYN202.
Other Income
VYNE also reported other income primarily derived from interest on cash, cash equivalents, and marketable securities. For the nine months ended September 30, 2024, other income was $3.1 million, compared to $0.7 million for the same period in 2023.
Financial Performance Summary
The financial performance of VYNE for the nine months ended September 30, 2024, is summarized below:
| Financial Metric | Value (in millions) |
|---|---|
| Net Loss | $(27.8) |
| Cash Used in Operations | $(25.0) |
| Cash, Cash Equivalents, and Marketable Securities | $70.2 |
| Accumulated Deficit | $(719.1) |
Future Funding Requirements
VYNE anticipates needing additional capital to fund its operations and further develop its product candidates. As of September 30, 2024, the company had no outstanding debt, and its liquidity is primarily dependent on cash flows from its existing agreements and potential future equity or debt financings.
Conclusion on Business Model
The business model of VYNE Therapeutics is heavily reliant on successful clinical development and commercialization of its product candidates. The company continues to explore partnerships and licensing agreements to enhance its revenue-generating capabilities.
VYNE Therapeutics Inc. (VYNE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- VYNE Therapeutics Inc. (VYNE) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of VYNE Therapeutics Inc. (VYNE)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View VYNE Therapeutics Inc. (VYNE)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.